Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celgene has announced positive results from an international clinical trial of Vidaza in patients with myelodysplastic syndromes that demonstrated an extension of overall survival compared to conventional care regimens.
Subscribe to our email newsletter
In the study, the two-year survival rate for patients treated with Vidaza was almost doubled with 50.8% compared to 26.2% for conventional care regimens (CCR). This improved survival extended across all patient subgroups. The median overall survival for patients treated with Vidaza in the study was 24.4 months compared to 15 months for CCR, demonstrating a survival benefit of 9.4 months.
The updated results reported that the survival impact was particularly impressive in patients with the deletion 7q cytogenic abnormality, which is considered to be a patient sub-group with particularly poor prognostics. It was also shown that the survival benefit of Vidaza is not attributable exclusively to those patients that experienced complete responses.
Alan List, chief, Division of Hematologic Malignancies of the Moffitt Cancer Center, said: “The results of the AZA-001 trial are the first to show that achievement of CR is not an obligate endpoint to extend overall survival in higher risk myelodysplastic syndromes (MDS).”